19 completed, 12 terminated, 4 active not recruiting, 3 withdrawn. 32 Phase 2, 15 Phase 1, 3 Phase 3.
Follow Clovis Oncology, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 68Ga-FAP-2286, Positron Emission Tomography (PET) - Liver Fibrosis, Pulmonary Fibrosis | Phase 1 | Completed | Thomas Hope | 16 | 2021-12-09 | 2025-03-21 |
| A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy nivolumab, ipilimumab, cabozantinib - Carcinoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Bristol-Myers Squibb | 2021-04-15 | 2023-12-19 | |
| A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma Rucaparib, Nivolumab - Leiomyosarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2020-11-05 | 2026-07-17 |
| Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study Rucaparib - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Completed | Grupo Español de Investigación en Cáncer de Ovario | 51 | 2020-07-29 | 2026-03-18 | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Rucaparib, Placebos - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | North Eastern German Society of Gynaecological Oncology | 42 | 2020-06-08 | 2024-11-15 |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Rucaparib, Copanlisib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Brown University | 13 | 2020-04-03 | 2025-05-04 |
| Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma Rucaparib, Ramucirumab, Nivolumab - Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma | Phase 1 / Phase 2 | Unknown | University of Kansas Medical Center | 34 | 2020-01-09 | 2023-02-01 |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma Rucaparib and Nivolumab - Small Cell Lung Cancer | Phase 2 | Completed | Zhonglin Hao | 33 | 2019-09-04 | 2024-10-22 |
| Pan Tumor Rollover Study Nivolumab, Ipilimumab, Cabozantinib - Cancer | Phase 2 | Recruiting | Bristol-Myers Squibb | 1500 | 2019-08-09 | 2026-10-30 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Lucitanib, Nivolumab - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 / Phase 2 | Suspended | Clovis Oncology, Inc. | 227 | 2019-07-29 | 2022-12-20 |
| The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Rucaparib, Bevacizumab, Atezolizumab - Endometrial Cancer, Uterine Carcinosarcoma | Phase 2 | Completed | Medical College of Wisconsin | 30 | 2019-07-19 | 2026-04-13 |
| Rucaparib in Nonmetastatic prOstAte With BRCAness Rucaparib - Prostate Cancer | Phase 2 | Terminated | University of Utah | 7 | 2019-05-20 | 2024-03-13 |
| Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Rucaparib, Placebo Oral Tablet - Metastatic Endometrial Cancer | Phase 2 | Completed | University of Colorado, Denver | 79 | 2019-03-06 | 2026-03-24 |
| Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Rucaparib, Abemaciclib, pembrolizumab & bemcentinib - Mesothelioma, Malignant | Phase 2 | Completed | University of Leicester | 186 | 2019-01-28 | 2026-08-17 |
| Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Pembrolizumab, Pemetrexed, Carboplatin - Stage IV Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 25 | 2018-12-24 | 2026-02-12 |
| Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Rucaparib - Prostate Cancer Metastatic | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2018-09-10 | 2024-10-16 |
| Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Rucaparib, Nivolumab - Prostate Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Terminated | University of Chicago | 12 | 2018-08-14 | 2021-03-09 |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Rucaparib, Bevacizumab - Cervical Cancer, Endometrial Cancer | Phase 2 | Completed | University of Oklahoma | 49 | 2018-06-29 | 2024-02-15 |
| A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Rucaparib, Radiotherapy - Breast Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 31 | 2018-05-23 | 2025-12-08 |
Showing 20 of 42. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (9) · Neoplasm Metastasis (6) · Endometrial Neoplasms (5) · Fallopian Tube Neoplasms (5) · Breast Neoplasms (4) · Ovarian Neoplasms (4) · Recurrence (4) · Adenocarcinoma (3) · Prostatic Neoplasms (3) · Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Cervical Neoplasms (2) · Acrocephalosyndactylia (1) · Adenocarcinoma Of Esophagus (1)
rucaparib (24) · Nivolumab (10) · rociletinib (7) · Bevacizumab (5) · E-3810 (5) · Docetaxel (3) · Ipilimumab (3) · Pemetrexed (3) · Ramucirumab (3) · atezolizumab (3) · pembrolizumab (3) · Capecitabine (2) · Cisplatin (2) · Gemcitabine (2) · cabozantinib (2)
United States (35) · Germany (10) · France (8) · Spain (8) · Australia (7) · Italy (7) · Netherlands (7) · United Kingdom (7) · Canada (5) · Argentina (4) · Belgium (4) · South Korea (4) · Taiwan (4) · Brazil (3) · Hong Kong (3)
Alfonso Yubero, Dr. (1) · Angel Qin, MD (1) · Anne Patsouris, MD (1) · Anwaar Saeed, MD (1) · Atif Khan, MD (1) · Benedito Carneiro, MD, MS (1) · Bradley Corr, MD (1) · Dean Fennell, PhD, FRCP (1) · Eileen O'Reilly, M.D. (1) · Erika Hamilton, MD (1) · Floor Backes, MD (1) · Jalid Sehouli, Prof. Dr. (1) · Jan Schellens, MD PhD (1)
PMID 35844029, PMID 12648575, PMID 15169803, PMID 19826121, PMID 20620859, PMID 21205755, PMID 21537039, PMID 22922531, PMID 23636398, PMID 24703918, PMID 24833920, PMID 24882554, PMID 25019571, PMID 25192616, PMID 25218906, PMID 25559473, PMID 25765070, PMID 25923550, PMID 26028255, PMID 26138335, PMID 26195695, PMID 26442214, PMID 26552419, PMID 27037982, PMID 27325856, PMID 27532025, PMID 28055103, PMID 28167507, PMID 28403786, PMID 28471727, PMID 28489510, PMID 28709704, PMID 28862931, PMID 29097493, PMID 29214032, PMID 29216356, PMID 29302014, PMID 29330207, PMID 33084183, PMID 33515503, PMID 34802864, PMID 35157829, PMID 35623069, PMID 35977756, PMID 38452035, PMID 38865673, PMID 38885246, PMID 40382284, PMID 40700852, PMID 8837607
2018 (2), 2016 (1), P30CA046934 (1), P50CA247749 (1)